Trifluoroacetic Acid
Trifluoroacetic acid is a corrosive organofluorine compound that is structurally analogous to, but stronger than, acetic acid. Available in various quantities and reagent grades, it is used in NMR spectroscopy, mass spectrometry, organic synthesis, etc.
Almost 100,000-fold more acidic than acetic acid, TFA is widely used in organic chemistry. TFA is used as a reagent in organic synthesis because of its properties: volatility, organic solvent solubility, and acidic strength. It is less oxidizing than sulfuric acid and is more readily available in its anhydrous form than some other acids . Other features include:
- Used in acid-catalyzed reactions, especially peptide synthesis (to cleave esters)
- Dissolves protein when mixed with liquid SO2
- Removes t-butyl derived side-chain protecting groups in Fmoc peptide synthesis
- Can remove the t-butoxycarbonyl protecting group in organic synthesis
- At low concentrations, acts as an ion-pairing agent for peptides and small proteins in organic compound liquid chromatography
- For acid-stable materials, can be a solvent for NMR spectroscopy
- Acts as a calibrant in mass spectrometry
- Used to produce trifluoroacetate salts
- An ingredient in adhesives, sealants, paints, and coatings
When TFA combines with bases and metals, especially light metals, a strong exothermic reaction occurs. When mixed with lithium aluminum hydride (LAH), the reaction is explosive.
Although nonflammable, TFA is corrosive to skin, eyes, and mucous membranes and requires careful use and handling. It is harmful when inhaled, causes severe skin burns and eye damage, and is toxic to aquatic organisms at even low concentrations.
TFA is also a product of the metabolic breakdown of the anesthetic agent halothane. It is the suspected cause of halothane-induced hepatitis.
Medchemexpress LLC Atwlppr peptide tfa | 98.6% | 954.00 | 5 MG
ATWLPPR Peptide TFA is a heptapeptide that acts as a selective neuropilin-1 inhibitor. It prevents VEGF165 binding to NRP-1 and is utilized in angiogenesis research, showing promise in reducing early retinal damage associated with diabetes.
- Inhibits VEGF165 binding to neuropilin-1 by 82% at 100 μM
- Preserves vascular integrity and reduces oxidative stress in vivo
- May decrease early retinal damage associated with diabetes
- Prevents increase of inflammation-associated proteins in the retina
Medchemexpress LLC CREBtide TFA | 98.7% | 1716.99 (free acid) | 5 MG
CREBtide TFA is a synthetic 13 amino acid peptide, a CREB (cAMP response element binding protein)-like peptide. It functions as a substrate for both Protein Kinase A (PKA) and Protein Kinase C (PKC).
- Solid appearance
- White to off-white color
- Amino acid sequence: Lys-Arg-Arg-Glu-Ile-Leu-Ser-Arg-Arg-Pro-Ser-Tyr-Arg
- Reported as a PKA and PKC substrate
- Apparent Km of 3.9 μM for phosphorylation by cAK
- Apparent Km of 2.9 μM for phosphorylation by cGK
Medchemexpress LLC CMD178 TFA | 99.7% | 964.05 | 5 MG
CMD178 (TFA) is a lead peptide that consistently reduces the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Ra signaling. It also acts as an inhibitor of STAT5 and inhibits Treg cells development.
- Reduces expression of Foxp3 and STAT5 induced by IL-2/s IL-2Ra signaling
- Inhibits STAT5
- Inhibits Treg cells development
Medchemexpress LLC Cppi9 Tfa | 99.9% | 1553.37 | 5 MG
CPP9 TFA is a small, amphipathic, cyclic cell-penetrating peptide (CPP) that binds directly to plasma membrane phospholipids and enters mammalian cells via endocytosis. Its efficient release from the endosome after cellular entry makes it suitable for intracellular delivery of therapeutic agents and chemical probes.
- Efficient release from endosome after cellular entry
- Suitable for intracellular delivery of therapeutic agents
- Suitable for intracellular delivery of chemical probes
- For research use only
Medchemexpress LLC Cpn-351 TFA | 912.11 (free base) | 1 MG
CPN-351 TFA (compound 9a) is a pentapeptide that acts as a selective antagonist of human NMUR1. Its antagonistic effect on human NMUR1 is 10 times higher than on NMUR2, making it useful in the study of inflammation.
- Selective antagonist of human NMUR1
- Antagonistic effect is 10 times higher on NMUR1 than NMUR2
- Can be used in the study of inflammation
- pA2 of 7.35 for NMUR1
- Kb of 45 nM for NMUR1
Medchemexpress LLC Cys-PKHB1 TFA | 1487.88 | 10MG
Cys-PKHB1 TFA is a peptide conjugated to PKHB1, functioning as a CD47 agonist peptide and a thrombospondin-1 peptide mimic with antitumor effects. It induces mitochondrial alterations, reactive oxygen species generation, and intracellular calcium accumulation, leading to calcium-dependent cell death in breast cancer cells. This compound also activates the immune system in breast cancer cells via immunogenic cell death.
- Conjugated peptide acting as a CD47 agonist
- Thrombospondin-1 peptide mimic
- Exhibits antitumor effects
- Induces mitochondrial alterations
- Promotes reactive oxygen species (ROS) generation
- Causes intracellular calcium (Ca+) accumulation
- Leads to calcium-dependent cell death in breast cancer cells
- Activates the immune system through immunogenic cell death
Medchemexpress LLC Sar441255 TFA | 99.9% | 4866.56 (free base) | 1 MG
SAR441255 TFA is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. It demonstrates high potency with balanced activation of all three target receptors. This compound shows positive acute glucoregulatory effects in diabetic obese monkeys, indicating its potential for metabolic and endocrine disease research, particularly in areas like obesity and type 2 diabetes.
- Potent unimolecular peptide receptor triagonist.
- Displays high potency with balanced activation of three target receptors.
- Shows positive acute glucoregulatory effects in diabetic obese monkeys.
- Relevant for research in metabolic diseases, including obesity and type 2 diabetes.
Medchemexpress LLC TP-5801 (TFA) | 99.6% | 641.48 | 100 MG
TP-5801 TFA is an orally active TNK1 (non-receptor tyrosine kinase) inhibitor with an IC50 of 1.40 nM, demonstrating anti-tumor activity. It inhibits TNK1-driven, BCR-ABL-driven, and IL-3-driven Ba/F3 cell growth, and TNK1-dependent L540 cell growth.
- Orally active
- Potent TNK1 inhibitor (IC50=1.40 nM)
- Demonstrates anti-tumor activity
- Inhibits growth of various cell lines (Ba/F3 and L540) relevant to TNK1-driven processes
- Shows efficacy in animal models, prolonging lifespan and inhibiting localized tumor growth without signs of toxicity
![Medchemexpress LLC Benzamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-2,5-dimethoxy-, 2,2,2-trifluoroacetate | 1336913-03-1 | 99.9% | 404.38 | 25 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000438811-Logo.png-250.jpg){kind=logo}
Medchemexpress LLC Benzamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-2,5-dimethoxy-, 2,2,2-trifluoroacetate | 1336913-03-1 | 99.9% | 404.38 | 25 MG
PSEM 89S TFA is a selective and brain penetrant agonist for ion channels, orthogonally selective for Q79G and L141F. It is intended for research use only.
- Activates layer 2/3 cortical neurons expressing PSAML141F,Y115F-5HT3 high conductance.
- Reversibly silences transfected neurons by reducing cellular input resistance.
- Reduces photostimulation-evoked feeding in mice with PSAML141F,Y115F-glycine receptor.
- Demonstrates good brain penetrance in mice after intraperitoneal administration.
- Suppresses fos in ChR2-expressing neurons in Agrp-cre mice.
- Shows rapid rise in serum and brain, cleared within 1 hour in C57BL/6 mice.
Medchemexpress LLC VTP-27999 (TFA) | 1013937-63-7 | 97.0% | C28H42ClF3N4O7 | 5 MG
VTP-27999 (TFA) is an alkyl amine Renin inhibitor useful for hypertension and end-organ diseases. This product is for research use only.
- Alkyl amine Renin inhibitor
- Useful for hypertension research
- Useful for end-organ diseases research
- For research use only
Apexbio Technology LLC FSLLRY-NH2 TFA 245329-02-6 (free base) 25mg
FSLLRY-NH2 TFA is a synthetic peptide antagonist targeting protease-activated receptor 2 (PAR-2) It is designed to block PAR-2 activation thereby inhibiting intracellular signaling cascades such as calcium mobilization and MAP kinase activation that underlie inflammatory responses nociceptive transmission and immune modulation FSLLRY-NH2 TFA exerts its biological activity primarily through competitive binding to PAR-2 preventing receptor activation and downstream signaling events Based on these pharmacological properties FSLLRY-NH2 TFA holds research potential in the study of inflammation-associated disorders and pain pathways
Medchemexpress LLC Batifiban TFA | 00-00-0 | 99.6% | 817.94 g/mol | C34H47N11O9S2 · xC2HF3O2 | 5 MG
Batifiban TFA is a cyclic peptide antagonist of platelet glycoprotein IIb/IIIa that inhibits platelet aggregation by blocking ligand binding such as vitronectin. Supplied as the trifluoroacetate (TFA) salt for research use, it is provided as a high-purity powder suitable for in vitro biochemical and cellular assays.
- Antagonizes platelet glycoprotein IIb/IIIa to inhibit aggregation.
- Blocks vitronectin binding to integrin receptors.
- Supplied as trifluoroacetate (TFA) salt for stability.
- High purity (~99.6%) suitable for biochemical assays.
- Available in small research pack sizes, including 5 mg.
- Store sealed, away from moisture and light; long-term storage at -80°C.
Medchemexpress LLC GHRF, mouse TFA (mouse growth hormone-releasing factor TFA) | 98.9% | 5032.74 | 25 MG
GHRF, mouse TFA is a mouse growth hormone-releasing factor. It is a peptide composed of 44 amino acids. This substance stimulates the release and synthesis of growth hormone. It is intended for research use only and not for sale to patients.
- Appearance: white to off-white solid
- Stimulates release and synthesis of growth hormone
- Suitable for research use only
- Peptide sequence: His-Val-Asp-Ala-Ile-Phe-Thr-Thr-Asn-Tyr-Arg-Lys-Leu-Leu-Ser-Gln-Leu-Tyr-Ala-Arg-Lys-Val-Ile-Gln-Asp-Ile-Met-Asn-Lys-Gln-Gly-Glu-Arg-Ile-Gln-Glu-Gln-Arg-Ala-Arg-Leu-Ser
- Store sealed, away from moisture
- Powder storage: -80°C for 2 years; -20°C for 1 year
- In-solvent storage: -80°C for 6 months; -20°C for 1 month
- In vitro solubility in DMSO: 100 mg/mL (requires ultrasonic)
- Comprehensive documentation available
Medchemexpress LLC Alvespimycin (17-DMAG) trifluoroacetate | 00-00-0 | MFCD08457919 | 99.0% | 730.77 g/mol | C34H49F3N4O10 | 5 MG
Alvespimycin TFA is the trifluoroacetate salt of 17-DMAG, a small-molecule inhibitor of heat shock protein 90 (Hsp90) used as a research reagent to study Hsp90-dependent signaling and anticancer mechanisms. The compound binds Hsp90 with an EC50 of 62 nM and is supplied as a high-purity, pale purple solid for laboratory use.
- Potent Hsp90 inhibitor (EC50 62 nM).
- Trifluoroacetate (TFA) salt form for consistent handling.
- High purity (reported ~98.97%).
- Molecular weight 730.77 g/mol.
- Pale purple solid appearance.
- Storage: sealed, away from moisture and light; in solvent, -80°C (6 months) or -20°C (1 month).